The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
CONCLUSIONS: Patients with established CVD in whom level of triglycerides is high would benefit from the treatment using icosapent ethyl, however, it is not a cost-effective from an Australian healthcare system perspective. The government may consider subsidising this medication given the clinical need but at a discounted acquisition cost.
PMID: 31285124 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Gao L, Moodie M, Li SC Tags: Eur J Intern Med Source Type: research
More News: Australia Health | Cholesterol | Internal Medicine | Lovaza | Omega 3 | Statin Therapy | USA Health